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Summary
Background In a longitudinal study assessing the WHO strategy for yaws eradication using mass azithromycin 
treatment, we observed resurgence of yaws cases with dominance of a single JG8 sequence type and emergence of 
azithromycin-resistant Treponema pallidum subspecies pertenue (T p pertenue). Here, we analyse genomic changes in 
the bacterial population using samples collected during the study.
Methods We did whole bacterial genome sequencing directly on DNA extracted from 37 skin lesion swabs collected 
from patients on Lihir Island, Papua New Guinea, between April 1, 2013, and Nov 1, 2016. We produced phylogenies 
and correlated these with spatiotemporal information to investigate the source of new cases and the emergence of five 
macrolide-resistant cases. We used deep amplicon sequencing of surveillance samples to assess the presence of 
minority macrolide-resistant populations.
Findings We recovered 20 whole T p pertenue genomes, and phylogenetic analysis showed that the re-emerging 
JG8 sequence type was composed of three bacterial sublineages characterised by distinct spatiotemporal patterns. Of 
five patients with resistant T p pertenue, all epidemiologically linked, we recovered genomes from three and found no 
variants. Deep sequencing showed that before treatment, the index patient had fixed macrolide-sensitive T p pertenue, 
whereas the post-treatment sample had a fixed resistant genotype, as did three of four contact cases.
Interpretation In this study, re-emergence of yaws cases was polyphyletic, indicating multiple epidemiological 
sources. However, given the genomic and epidemiological linkage of resistant cases and the rarity of resistance alleles 
in the general population, azithromycin resistance is likely to have evolved only once in this study, followed by onward 
dissemination.
Funding Wellcome and Provincial Deputation of Barcelona.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Yaws, caused by the bacterium Treponema pallidum 
subspecies pertenue (T p pertenue), is a neglected tropical 
disease and a major cause of morbidity in regions of 
Africa, Asia, and the South Pacific.1,2 Infection with 
T p pertenue is clinically apparent in the early stages, but 
population-level disease control is complicated by the 
bacterium’s ability to undergo periods of asymptomatic 
latency that can span five to ten years, thus evading 
strategies targeting only clinically active cases.1 This 
challenge influenced WHO in designing its Morges 
Strategy3 for yaws eradication using mass drug 
administration (MDA) of single-dose azithromycin for all 
community members, regardless of infection status.
In a longitudinal study, which was part of a yaws 
elimination programme including more than 
16 000 residents of Lihir Island, Papua New Guinea, a 
single MDA with azithromycin reduced the prevalence of 
yaws from 1·8% (238 of 16 092) to 0·1% (17 of 17 339) 
after 18 months,4 but infection began to re-emerge after 
24 months, with a significant increase (difference 
0·3%; 95% CI 0·1–0·4; p<0·0001) in prevalence to 
0·4% (51 of 18 836) at 42 months.4 We previously reported 
the findings of baseline and follow-up surveys,4 with use 
of a novel multilocus sequence typing (MLST) scheme5 
to analyse 239 samples, and showed a transition from a 
diverse population of T p pertenue sequence types before 
the commencement of MDA to the dominance of a 
single sequence type (JG8) 24 months after MDA.4 We 
also reported the detection of five cases of T p pertenue 
with genotypic resistance to azithromycin mediated by 
A2059G mutations in the 23S ribosomal genes (one of 
two mutations, along with A2058G, known to cause 
resistance in T pallidum), all belonging to the 
JG8 sequence type.4
In this study, we validated the previous molecular 
typing system using whole genomes sequenced directly 
from clinical swab DNA,6 and we used the increased 
resolution provided by genomic tools in combination 
with additional epidemiological data to conduct a 
Articles
e264 www.thelancet.com/microbe   Vol 1   October 2020
Biology (I2SysBio), 
Valencia, Spain 
(Prof F Gonzalez-Candelas PhD); 
CIBER in Epidemiology and 
Public Health, Valencia, Spain 
(Prof F Gonzalez-Candelas); 
Clinical Research Department 
(M Marks PhD) and Department 
of Infectious and Tropical 
Diseases (Prof N R Thomson), 
Faculty of Infectious and 
Tropical Diseases, London 
School of Hygiene & Tropical 
Medicine, London, UK; Hospital 
for Tropical Diseases, London, 
UK (M Marks); and Division of 
Public Health, School of 
Medicine and Health Sciences, 
University of Papua 
New Guinea, Port Moresby, 
Papua New Guinea (O Mitjà)
Correspondence to: 
Dr Mathew A Beale, Parasites and 
Microbes Programme, Wellcome 
Sanger Institute, Wellcome 
Genome Campus, Hinxton 
CB10 1SA, UK 
mathew.beale@sanger.ac.uk
or
Dr Oriol Mitjà, Lihir Medical 
Center, International 
SOS-Newcrest Mining, Lihir 
Island, Papua New Guinea 
omitja@flsida.org genomic epidemiology investigation. We aimed to 
determine the epidemiological mechanisms and source 
of infection leading to re-emergence of yaws cases after 
MDA. We also investigated the epidemiological links 
between cases of drug resistance and assessed how 
macrolide resistance emerged under the selection 
pressure applied by single-dose MDA.
Methods
Study population
We included all patients with PCR-confirmed T p pertenue 
during a yaws elimination programme conducted 
between April 1, 2013, and Nov 1, 2016, in Lihir Island, 
Papua New Guinea, covering a population of more than 
16 000. All participants, or their guardians for participants 
younger than 16 years, provided oral informed consent to 
be screened and treated during the study. Written 
informed consent was obtained from all patients with 
lesions before enrolment. The protocol was approved by 
the National Medical Research Advisory Committee of 
the Papua New Guinea Ministry of Health (MRAC 
number 12.36).
Data and swab collection
We matched laboratory results to case reports containing 
demographic data (age, sex, place of origin, and place of 
residence) and clinical data (disease stage and duration). 
We investigated possible contact with the known drug-
resistant cases and recorded sociodemographic risk 
factors (family relations, regular place of socialising, place 
of religious worship, and regular travel to or visitors from 
another village).
Swabs of skin lesions from patients with suspected 
yaws were taken before MDA (April, 2013; survey 
round 1), and at 6-monthly surveys throughout the 
subsequent 42 months (to October, 2016; survey 
rounds 2–8), as previously described.4 PCR performed on 
DNA extracted from swabs identified 239 of 777 samples 
to be T p pertenue-positive,4,7 and from previous MLST 
results,5 193 samples were fully typed and available. 
Macrolide resistance single nucleotide polymorphisms 
(SNPs) were initially detected by restriction fragment 
length polymorphism (RFLP).7,8
Genome sequencing
Of the 193 available samples, we stratified by MLST type, 
geography, and surveillance round, randomly selecting 
samples within the strata using computer-generated 
random lists. We filtered these samples based on a 
quantitative PCR (qPCR) cycle threshold (Ct) of less 
than 32, as described previously.9 Additionally, we 
selected six samples from five patients regardless of 
qPCR Ct value, because of their involvement in a 
suspected transmission chain (based on epidemiology 
and observed treatment failure).
Whole genome sequencing (WGS) was performed 
directly on T p pertenue DNA extracted from 37 samples 
using the pooled sequence-capture approach, as 
previously described (appendix 1 p 3).6,9
Research in context
Evidence before this study
We searched PubMed using the terms “yaws”, “Treponema 
pallidum”, “mass treatment”, and “azithromycin”, without date 
or language restrictions. The original search was done in 
August, 2019, with regular monitoring of newly published 
research by MAB thereafter. Mass drug administration (MDA) 
using azithromycin (single-dose 30 mg/kg, maximum 2 g) has 
been a successful strategy to reduce yaws prevalence in 
endemic communities, with trials done in Papua New Guinea 
and Ghana. However, no long-term follow-up studies have 
been done other than in Papua New Guinea, where a resurgence 
of yaws cases was observed 24 months after MDA. Multilocus 
sequence typing (MLST) showed a change in Treponema 
pallidum subspecies pertenue (T p pertenue) to a single dominant 
JG8 type, and identified resistant strains with the same MLST 
type, but this method lacked the resolution to determine the 
epidemiological mechanism leading to yaws re-emergence and 
the manifestation of macrolide resistance.
Added value of this study
To our knowledge, this is the first study to use whole genome 
sequencing (WGS) for a detailed investigation of T p pertenue 
transmission and to apply deep amplicon sequencing to 
T p pertenue macrolide-resistance mutations. Using the 
increased resolution of WGS over other techniques, we showed 
that re-emergence of yaws after MDA was the result of at least 
three distinct bacterial sublineages with different 
spatiotemporal properties (probably due to several infected 
people missing treatment), rather than a single source, and that 
patients with macrolide-resistant yaws had genomically 
indistinguishable T p pertenue, indicating a recent common 
ancestor, and possibly a recent chain of transmission 
originating from the index case. Deep amplicon sequencing 
corroborates that PCR-tested macrolide-sensitive samples do 
not harbour resistant minority populations at detectable levels.
Implications of all the available evidence
Our data suggest that yaws re-emergence after MDA was driven 
by multiple sources, and therefore we recommend higher 
population coverage and intensive post-MDA surveillance. 
These data show that resistance probably evolved once during 
the trial, rather than being widespread. We recommend careful 
monitoring of affected communities during post-MDA follow-
up in order to rapidly detect new emergence of azithromycin 
resistance, and the consideration of alternative treatments for 
cases detected after MDA.
See Online for appendix 1
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Phylogenomic analysis
We did a phylogenomic analysis of the study genomes, 
contextualised using 20 publicly available T p pertenue 
genomes derived from both humans and non-human 
primates,6,10–14 and one T pallidum subspecies endemicum 
genome as an outgroup (BosniaA;15 appendix 1 pp 4–6). 
We mapped sequencing reads to a common reference 
genome (Samoa D) to generate a multiple sequence 
alignment, including genomes for which we had sufficient 
coverage: minimum five reads per site, to call variants for 
at least 843 104 (74%) of 1 139 330 genomic reference 
positions. We screened our alignment for recombination 
using Gubbins v1.4.10,16 and we used IQ-Tree v1.6.10 to 
infer a maximum likelihood phylogeny from the resulting 
recombination-masked SNP alignment.9,17 We tested the 
robustness of our tree topology through Bayesian 
reanalysis using PhyloBayes v3.0 (appendix 1 pp 4–5).18 To 
assess the phylogenetic patterns underlying clonal 
expansion of the JG8 sequence type, we did ancestral 
reconstruction of the SNPs along the phylogenetic 
branches within the JG8 lineage and used rPinecone19 to 
define phylogenetically clustered samples, as previously 
described,9 based on separation by more than four SNPs. 
To analyse the phylogenomic context of a sample yielding 
only 54% genome coverage, we subsampled the multiple 
sequence alignment to include only supported sites for 
that genome (appendix 1 p 5).
Deep sequencing analysis
To detect mixed resistance alleles and investigate how the 
A2059G macrolide resistance mutation first evolved, we 
designed discriminatory PCR primers specific to the 
regions flanking the individual copies of 23S rDNA 
(T p pertenue has two copies of the gene), and generated 
amplicons for each operon for six samples (in triplicate) 
from five patients with resistant strains and two samples 
(single replicate) with sensitive strains from epidemio-
logically linked participants (appendix 1 p 3). To investigate 
the broader prevalence of mixed 23S T p pertenue 
resistance alleles in Lihir patients, we stratified samples 
by survey round only, selecting 31 samples within the 
strata from individuals infected with macrolide-sensitive 
T p pertenue, and used the same method to amplify the 
T p pertenue 23S operons (single replicate). Amplicons 
were sequenced (Illumina MiSeq, Illumina, San Diego, 
CA, USA), and the relative proportions of sequencing 
Figure 1: Maximum likelihood whole genome sequencing phylogeny of 
40 T p pertenue genomes, including 20 genomes from Lihir, 
Papua New Guinea
The JG8 MLST type represents an extremely clonal lineage of T p pertenue found 
in Lihir and the Solomon Islands, with all JG8 samples separated by less than 
20 single nucleotide polymorphisms. Types TD6 and SE7 are genomically 
distant. Three genomes carrying the A2059G mutation are shown. Branches 
with Ultra-Fast bootstrap values of 95% or higher are labelled. Branches are 
scaled by nucleotide substitutions per site. Sequence types shown comprise 
alleles taken from directly amplified and sequenced T p pertenue MLST genes or 
those determined in silico using the genome sequence data. New allelic 
signatures not described in the Godornes MLST scheme5 are labelled white. The 
presence of A2059G mutations was assessed previously by restriction fragment 
length polymorphism if available,4 or in silico from the genome sequence. 
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reads corresponding to each gene copy and each allele 
(A2058G, A2059G) were analysed, using both allele 
counting and read haplotype counting approaches 
(appendix 1 pp 3–4).
Role of the funding source
The funders had no role in study design, data collection, 
data analysis, data interpretation, or writing of the report. 
All authors had full access to all the data in the study and 
MAB, NRT, and OM had final responsibility for the 
decision to submit for publication.
Results
Of 232 patients with T p pertenue-positive samples 
available from the Lihir trial, we selected 72 as examples 
of T p pertenue diversity, covering the full geographic and 
temporal range of the study period. From these, we 
performed WGS directly on DNA extracted from clinical 
swabs for 31 samples with qPCR Ct of less than 32, 
generating 17 high-quality genomes. Six additional 
samples, selected because they were collected from 
five patients involved in a suspected transmission chain, 
yielded three high-quality genomes and one partial 
genome. In total, we recovered 20 near-whole T p pertenue 
genomes with more than 74% genome coverage from the 
Lihir trial samples (appendix 1 pp 9–11). Refining our 
previous observations,9 we recovered no high-quality 
genomes from samples with qPCR Ct of more than 30 
(appendix 1 p 9, appendix 2).
Of 20 genomes recovered, 16 were of the JG8 sequence 
type (figure 1). In-silico MLST of seven closely related 
T p pertenue genomes from the Solomon Islands6 
determined that these were also sequence type JG8 under 
the T p pertenue MLST scheme.5 In addition, WGS 
showed a large putative recombination event, previously 
described in the Solomon Island T p pertenue strains6 
and covering ten coding sequences (spanning 
TPESAMD_0856a to TPESAMD_0866), was also present 
Figure 2: JG8 subtree phylogeny
Phylogeny includes 16 genomes from Lihir, Papua New Guinea, and seven from the Solomon Islands. Branches are scaled and labelled according to the absolute count of non-recombining base 
substitutions (relative to the parent and child nodes determined by ancestral state reconstruction). Tip labels for macrolide-resistant strains are shown in red. Coloured tracks show phylogenomic 
sublineage, village, survey round, and whether the patient had a recent history (previous 3 months) of travel off the island. Village data were unavailable for three patient samples (shown in white). 
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in the JG8 genomes from Lihir (appendix 1 p 12). 
Phylogenomic analysis of all available T p pertenue 
genomes showed that the JG8 sequence type is extremely 
clonal (figure 1), with all JG8 genomes separated by 
fewer than 20 pairwise SNPs, and the topology of the 
JG8 subtree was built on 28 phylogenetically informative 
sites (appendix 1 p 13). Although low coverage in some 
sites might hide SNPs that could affect the JG8 subtree, 
Bayesian reanalysis confirmed that we had determined 
the most probable topology (appendix 1 pp 13, 14).
Although the majority of Lihir genomes (16 of 20) 
recovered were part of the clonal JG8 sequence type, one 
genome recovered from a sample taken early in MDA 
follow-up (R3-SAL-007; round 3) was of the TD6 sequence 
type, separated from the JG8 genomes by a long branch 
of 133 base substitutions. Three genomes from Lihir 
were sequence type SE7, forming a distinct phylogenomic 
clade more closely related to genomes from Indonesia or 
Western Samoa than to the JG8 sequence type genomes 
from Lihir (figure 1).
We investigated whether the spread of the JG8 sequence 
type after MDA could be explained by a single clonal 
expansion, or through multiple epidemiological routes. 
Using ancestral reconstruction of the 28 phylogenetically 
discriminatory SNPs in the JG8 sequence type, we found 
five distinct phylogenetic clusters (sublineages) separated 
by at least four SNPs, including three sublineages from 
Lihir (figure 2; sublineages JG8.c2, JG8.c3, JG8.c5). 
Sublineage JG8.c2 samples (n=11) were found in five 
different villages (Hurtol, Landolam, Lissel, Samo, and 
Zuen) and sublineage JG8.c3 samples (n=5) were found 
in three villages (Kosmayun, Putput, and Zuen); a 
sublineage JG8.c5 sample from Mazuz village was 
separated from the JG8.c3 genomes by five SNPs. All 
three JG8 sublineages from Lihir were detected in the 
later rounds of post-MDA follow-up, indicating they were 
all involved in yaws re-emergence. As figure 2 shows, 
rather than being the result of a single clonal expansion, 
the cases had distinct geographical, temporal, 
and phylogenomic properties, reflecting separate 
epidemiological and evolutionary histories. Five of 
eleven JG8.c2 genomes were sampled from patients with 
a history of recent travel outside of Lihir (in the past 
3 months).
We intentionally oversampled and examined a putative 
transmission network of five cases with treatment failure;4 
all of the T p pertenue samples from these cases were of the 
JG8 sequence type, and all carried the A2059G mutation 
linked to azithromycin resistance in T pallidum subspecies 
pallidum.8 We identified patient 1 (sample R7-KOS-003) as 
representing the earliest macrolide-resistant case (index 
case; June, 2016), with the patient reporting having an 
ulcer for at least 3 months before formal diagnosis. 
7 months earlier (October, 2015), patient 1 had been 
diagnosed and treated with azithromycin for yaws; RFLP 
testing showed that this earlier infection was macrolide-
sensitive (A2059). Epidemiological tracing identified 
potential transmission links between all five resistant 
cases (figure 3); four of the children were from the same 
village (Kosmayun), and the index case (patient 1) was a 
sibling of patient 2, playmate of patients 3 and 4, and 
school friend of patient 5 (sample R8-LMC-004). This link 
between patients 1 and 5 was not described previously4 
and was discovered only during follow-up interview. 
Patient 5 is from Zuen village, 7 km from Kosmayun, but 
both patients attend a school in Sale, which is equidistant 
between the villages. Two additional cases from Kosmayun 
(patients 6 and 7) epidemiologically linked to patient 4 
(sibling and playmate) were identified within the 
timeframe of the investigation, both of whom were 
infected with macrolide-sensitive (A2059) T p pertenue.
Figure 3: Epidemiological relationships between macrolide-resistant samples
Episode duration before sampling is based on patient reporting. Patient 1, living in Kosmayun village, was positive 
for wild-type T p pertenue in October, 2015, but follow-up in June, 2016, identified A2059G resistant T p pertenue in 
patient 1 and their sibling patient 2. A third patient (patient 5) was identified in Zuen village in July, 2016 (school 
friend of patient 1). Two more patients from Kosmayun (playmates of patient 1) were detected with resistant 
T p pertenue in November, 2016. All patient samples were typed as JG8, and of three near-whole genomes 
recovered from three patients, all were identical over the length recovered. A partial genome (54% of length 
covered) was obtained from the index case (patient 1, R6-KOS-002), which was identical to the others over the 
common regions (appendix 1 p 15). In determining the origin of patient 1’s resistant sample, it was not possible to 
conclusively discriminate between relapsed infection and de-novo reinfection from an unsampled patient. 
T p pertenue=Treponema pallidum subspecies pertenue.
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We were able to recover near-complete T p pertenue 
genomes from patients 3, 4, and 5. We compared the 
28 discriminatory sites from these three genomes 
(R8-KOS-004, R8-LMC-004, and R8-KOS-007); in 
three-way pairwise genome comparisons we identified 
no SNPs. However, because of insufficient coverage, 
five or six sites in each pairwise comparison were 
excluded, and we could not rule out the possibility of a 
SNP being present at those excluded positions 
(appendix 1 p 6). The three genomes were otherwise 
identical. Another JG8 genome (R7-PUT1–002) was also 
identical to the other three samples over the 28 sites 
(apart from 3–5 undetermined sites), but this sample 
lacked either an epidemiological link to the other cases, 
or the resistance allele (variants in the 23S region, 
including A2059G, were excluded from pairwise 
counts). These four genomes together comprise 
sublineage JG8.c3 in figure 2. We attempted to sequence 
T p pertenue from the pretreatment sample from 
October, 2015, for patient 1 (R6-KOS-002; lacking the 
macrolide resistance allele), but due to low pathogen 
load we were only able to recover 54% (625 633 of 
Figure 4: Deep amplicon sequencing and evaluation of 23S A2059 allele frequencies
Samples within the putative transmission network are either fixed at A2059A (blue) or A2059G (red), with the exception of sample R8-KOS-007 (patient 4). There 
was no evidence of minority resistance alleles in any samples outside of the putative transmission network. Because there are two genomic copies of the 23S gene, all 
samples were tested using operon-specific PCR amplicons. Samples from the putative transmission network were tested in triplicate and are labelled by patient. 
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1 139 330 sites) of the genome; R6-KOS-002 was identical 
to R8-KOS-007 and R8-KOS-004 over the high-quality 
common recovered regions, and phylogenetic 
reconstruction using the 625 high-quality SNP sites 
from this genome replicated the sample groupings of 
figures 1 and 2 (appendix 1 p 15).
We used deep amplicon sequencing (figure 4, 
appendix 1 p 16, appendix 3) to investigate the evolution 
of T p pertenue drug-resistance variants in patient 1. For 
the earlier wild-type (A2059) sample (R6-KOS-002), we 
obtained sequencing coverage of more than 8000 × for 
each 23S rRNA allele, with three technical replicates. A 
maximum of 18 reads (<0·22% A2059G) supported the 
A2059G mutation in any one replicate, which was well 
below our threshold for minority variant calling (1%) and 
equivalent to background sequencing error (figure 4). 
This result could be because the mutation was present 
but below our limit of detection; alternatively, the 
mutation could have appeared subsequent to this sample 
being taken, or it could represent a case of reinfection, 
transmitted from an unsampled individual. Deep 
sequencing from patient 1’s post-treatment sample, as 
well as three of four contact cases with A2059G identified 
using RFLP, showed a fixed genotype, with more than 
99% of sequencing reads (from a minimum of 797 reads) 
carrying the A2059G mutation at both 23S copies 
(figure 4). In patient 4 (sample R8-KOS-007), we found 
only 91% of reads (range 87–95% over three technical 
replicates, consistent for both gene copies) corresponded 
to A2059G. Manual examination of both the deep 
sequencing amplicon reads and the WGS reads (derived 
from a different DNA extract of the same swab) showed a 
mixture of correctly paired and mapped reads with both 
alleles at position A2059, consistent with a heterozygous 
SNP (ie, a mixed population of sensitive and resistant 
bacteria). Further analysis of read haplotypes also 
supported that this sample contained a mixed population 
of resistant and sensitive bacteria (appendix 1 p 16). 
We had insufficient coverage from WGS to robustly 
probe genome-wide minority variants and exclude 
the possibility of co-infection in this patient. Deep 
sequencing of samples from patients 6 and 7, who were 
close contacts of patient 4, showed that these were fixed 
wild-type (A2059).
To investigate the prevalence of minority T p pertenue 
drug-resistance variants more broadly, 31 samples were 
selected from throughout the post-MDA surveillance 
period, except rounds 1, 2, and 4 due to insufficient 
residual DNA (appendix 1 pp 10–11), from participants 
residing in 15 of 28 villages on Lihir Island. Samples 
were taken from nine female and 22 male participants 
(median age 9 years [IQR 7–12]), with four of seven MLST 
types represented. Using the same deep amplicon 
sequencing approach (but with a single technical 
replicate), we found no evidence for low-frequency 
macrolide resistance at either position A2058G or 
A2059G in any of these samples (figure 4).
Discussion
Building upon our previous work in which we resolved 
yaws molecular diagnostic failures through genomics,6 in 
this study, we used the increased resolution afforded by 
WGS phylogenomic analyses to investigate post-MDA 
yaws re-emergence and macrolide resistance. Single-dose 
mass treatment with azithromycin has been a valuable 
tool in low-income and middle-income countries, directed 
towards the elimination of both trachoma20,21 and yaws.22,23 
In the context of yaws eradication efforts, re-emergence 
of cases after treatment and bacterial drug resistance 
represent critical issues with this strategy.
Although a small proportion of cases identified during 
follow-up were of genetically distinct MLST types (eg, SE7), 
consistent with importation of strains from outside Lihir,4 
the majority of re-emergent cases were of the endemic 
JG8 sequence type. The MDA intervention had a lasting 
effect on the T p pertenue population structure in Lihir, 
with a diverse T p pertenue population being replaced by a 
clonal expansion of the JG8 sequence type, the most 
common lineage before the MDA.4 Using high-resolution 
WGS, we showed that the re-emerging JG8 samples were 
split into at least three distinct phylogenetic sublineages. 
Contextualised by our previous estimate that the mean 
molecular clock rate of T pallidum is approximately one 
SNP every 4–5 years,9 the geographical dispersal and 
genetic separation of samples such as R8-MAZ-003 in 
sublineage JG8.c5 from other samples by five SNPs is 
indicative of distinctly different evolutionary histories 
within the JG8 sequence type. These sublineages support 
clinical observations that MDA treatment escape is related 
to multiple epidemiological routes rather than a single 
point source (either local or imported), consistent with 
multiple cases of missed MDA, followed by reactivation of 
latent T p pertenue.
We note that five of 11 patients infected with sublineage 
JG8.c2, the largest and most geographically dispersed 
JG8 sublineage studied, had a history of travel away from 
Lihir. This observation could suggest importation of the 
JG8.c2 sublineage, but we had insufficient sampling to 
address this.
We described the genomic relatedness of T p pertenue 
among the first five people diagnosed with macrolide-
resistant yaws, representing 2·4% (five of 209) of post-
MDA cases. Macrolide resistance in T pallidum is thought 
to be caused by one of two mutations targeting the two 
genomic copies of the T p pertenue 23S gene: A2058G has 
been linked to multiple independent evolutionary events 
in T p pallidum,9 whereas A2059G (the only variant detected 
in this study) is less common. In this study, all individuals 
with resistant T p pertenue were epidemiologically linked, 
had the same A2059G mutation, and JG8.c3 genomes 
sequenced from three cases were identical over the 
supported sites. Given the thoroughness of the surveillance 
and RFLP resistance testing in the post-MDA study 
population, it is unlikely that we failed to identify additional 
resistant T p pertenue cases. The most parsimonious 
See Online for appendix 3
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interpretation of these data is that a single, de-novo 
evolutionary mutation conferred macrolide resistance, 
followed by onward transmission. An alternative explana-
tion for the cluster of macrolide-resistant T p pertenue 
described in this study would be independent A2059G (but 
not A2058G) resistance mutations arising in five separate 
patients infected with genomically identical T p pertenue, 
with the epidemiological linkage being coincidental.
We did not detect the A2059G mutation in the index 
case (patient 1) before treatment, and this patient’s initial 
lesion resolved after treatment with azithromycin, 
suggesting the mutation was acquired after commence-
ment of treatment. This acquisition could either be due to 
selection of de-novo resistance in the original strain, or 
through reinfection from an unsampled individual during 
the latter months of the treatment phase, when the drug 
levels in tissue were waning. Such a scenario of reinfection 
during the subtherapeutic period might explain selection 
of a resistant subpopulation.
Independent analyses of the sample from patient 4 
indicated that this patient’s T p pertenue was heterozygous 
for the macrolide resistance allele in both copies of 
23S rRNA. Assuming this epidemiologically linked 
patient was indeed part of the same transmission 
network (rather than a second de-novo evolutionary event 
or transmission from an unsampled resistant case), we 
envisage two possible explanations for this heterozygosity. 
First, the patient could have been co-infected with a 
second wild-type JG8 T p pertenue strain; we were unable 
to exclude the possibility of co-infection through minority 
variant analysis of the WGS reads. Of note, patient 4 
shared close epidemiological links with patients 6 and 7, 
who were both infected with wild-type JG8 sequence-type 
T p pertenue, making co-infection a plausible scenario. 
Second, the patient’s T p pertenue A2059G allele could 
have reverted to wild-type. During this study, we 
identified samples with a qPCR Ct as low as 
23·8 (13 003 copies/µL; R2-SR-001B; appendix 1 p 9, 
appendix 2), obtained from a DNA extraction of 100 µL. 
Ulcer swabs can therefore contain more than 
1 300 000 bacterial T p pertenue copies, and this represents 
a small subsample of the bacteria present in a yaws ulcer. 
We therefore consider it likely that, given time, such a 
mutation to wild-type A2059 could have occurred in a 
lesion simply by chance. However, for any mutation to 
reach a frequency of 9% in a lesion (as detected in 
patient 4) implies selective pressure (eg, fitness cost). We 
had insufficient data to conclusively discriminate 
between these two scenarios, but we consider co-
infection to be a more likely scenario.
Although resistance is likely to have evolved only once 
in this study, there is clearly a risk of further emergence. 
Our broader sampling and deep sequencing from 
patients throughout the survey period showed that, in 
this study, T p pertenue samples that were sensitive 
according to RFLP methods did not harbour A2058G or 
A2059G mutations, even at low frequency. Although 
these mutations might occur naturally within a patient at 
low frequency, we would expect them to be selectively 
neutral or slightly detrimental, and to disappear within a 
few generations without the selective pressure of drug 
exposure to drive them to fixation. It will be important in 
future work to characterise appropriate thresholds at 
which a minority resistance allele is likely to evolve into a 
resistant case after drug exposure, as has been done in 
the HIV field.24 Analysis of global syphilis lineages 
suggests that once macrolide resistance evolves and is 
selected for in a patient, it can persist in lineages,9 
without any evidence of a fitness cost of possessing such 
variants. Broader MDA with azithromycin could 
therefore promote resistance in T p pertenue, and 
consideration should therefore be given to alternative 
treatment options and resistance mitigation strategies.
Our study has several strengths. First, we combined 
detailed epidemiological analysis of spatiotemporal data 
and phylogenomic reconstruction of bacterial genomes, 
resulting in the best evidence available to understand 
yaws transmission and bacterial population evolution 
after MDA. The use of genomics enabled previously 
unachievable levels of strain discrimination, allowing us 
to determine that resurgent JG8 cases originated from 
multiple sources rather than a single point source. We 
recovered 20 near-complete T p pertenue genomes, 
substantially increasing the number of published 
genomes. However, the inherent limitations of high 
contamination and low bacterial load in yaws swabs 
prevented us from sampling the population more 
completely, such that we might have missed unsampled 
diversity. Furthermore, although we attempted to make 
our sample selection representative of the population 
structure in Lihir, sampling was not random and 
laboratory staff were not blinded to clinical or demographic 
data, which could have introduced bias. Second, we 
recovered near-complete T p pertenue genomes from three 
macrolide-resistant cases, and moving beyond MLST-level 
groupings, we showed that these T p pertenue genomes 
were virtually identical, indicating that they share a recent 
common ancestor and perhaps a single chain of 
transmission. Finally, we applied deep amplicon 
sequencing to search for minority T p pertenue resistance 
alleles, showing that RFLP-tested macrolide sensitive 
samples do not harbour resistant T p pertenue 23S minority 
alleles, as well as providing evidence supporting the de-
novo evolution of the T p pertenue A2059G mutation 
within a single patient or lesion.
Our study provides new scientific data about the 
characteristics, epidemiology, and transmission dynamics 
of yaws. The genomic dissection renders compelling, 
high-resolution evidence on the factors that underpin yaws 
re-emergence and drug resistance after a single round of 
MDA. These data will support improvement of policies 
and strategies to eradicate yaws, and will also inform 
strategy for MDA campaigns in other diseases for which 
population data are sparse. As part of the global eradication 
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initiative, MDA campaigns against yaws have the potential 
to significantly reduce transmission of infection in many 
high-prevalence areas. In these settings, flexible and 
urgent solutions are needed for a rational approach to 
counteract recrudescence of infection and drug resistance. 
We recommend high MDA coverage to reduce the number 
of missed people with active or latent yaws (eg, non-
cooperation, people working elsewhere), and intensive 
post-MDA surveillance for the detection of the residual 
yaws cases and to control importation and onward 
transmission of new infections. We also recommend 
careful monitoring of affected communities during MDA 
follow-up in order to rapidly detect and retreat individuals 
with clinical treatment failure using alternative treatments 
(eg, benzathine benzylpenicillin). If emergence of 
azithromycin resistance is confirmed in the lab, then we 
recommend implementing a comprehensive strategy to 
mitigate resistance dissemination, including treatment of 
all new yaws cases and their contacts in the affected area 
with alternative regimens. Genomic data can play a central 
role in monitoring and anticipating the dynamics of 
transmission of yaws to minimise the risk of re-emergence.
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